# Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

> **NCT01187966** · PHASE3 · COMPLETED · sponsor: **Newron Pharmaceuticals SPA** · enrollment: 669 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Safinamide
- **DRUG:** Safinamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01187966
- **Lead sponsor:** Newron Pharmaceuticals SPA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-10
- **Final completion:** 2009-02
- **Target enrollment:** 669 (ACTUAL)
- **Last updated:** 2010-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01187966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01187966, "Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01187966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*